This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Investor Alert: Federman & Sherwood Reminds Investors With Losses In Invacare Corporation Of Upcoming Deadline In Securities Class Action Lawsuit

Federman & Sherwood announces that on May 24, 2013, a class action lawsuit was filed in the United States District Court for the Northern District of Ohio against Invacare Corporation (NYSE: IVC) for possible federal securities laws violations surrounding the Company’s failure to disclose adverse facts about IVC during the Class Period (7/22/2010 through 12/7/2011). More specifically, the Complaint alleges the Company was issuing a series of false or misleading statements, or was failing to disclose, IVC’s non-compliance with FDA guidelines and Current Good Manufacturing Practices (“CGMP”). The Complaint also alleges the Company was suffering from widespread operational, quality and regulatory deficiencies, and had received a series of warning letters from the FDA identifying serious compliance violations at its two major U.S. manufacturing facilities. Allegedly, all of these facts were concealed from investors. On January 4, 2011, the FDA released a warning letter to the public identifying the CGMP violations and “recurring” consumer complaints concerning the safety of the Company’s medical beds. That day IVC’s stock declined $1.38 per share, to close at $29.29 per share on that date. However, the Complaint alleges IVC continued to downplay the significance of the Company’s compliance issues, despite receiving 2 more FDA warning letters, which were also concealed from investors. On December 8, 2011, the Company issued a press release announcing that the FDA intended to suspend certain IVC operations until the Company’s manufacturing facilities became FDA compliant. Upon this news, the Company’s stock prices declined $5.88 per share. The Complaint therefore alleges violations of Section 10(b) and Section 20(a) of the Securities Exchange Act, and Rule 10b-5 promulgated thereunder.

If you purchased Invacare Corporation shares between July 22, 2010 and December 7, 2011, have large losses as a result of your trades during this time period, and wish to join this litigation as a potential lead plaintiff, please contact our office as soon as possible. Investors only have until Tuesday, July 23, 2013 to move the court for consideration as a court-appointed lead plaintiff in this action. Our firm seeks to recover damages and losses on behalf of the entire Class. Federman & Sherwood has extensive nationwide experience and expertise in prosecuting securities litigation involving financial fraud. If you wish to join this class action or have further questions, please contact at

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs